Suchergebnisse - "Ziepert, Marita"

PubPharm (8)

1

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

enthalten in: Blood | 2021

von Schmitz, N. | Truemper, L. | Bouabdallah, K. | +38

CommentIn: Blood. 2021 May 13;137(19):2570-2571. - PMID 33983423

2

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma : 10-year follow-up of a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2021

von Frontzek, F. | Ziepert, M. | Nickelsen, M. | +18

CommentIn: Lancet Haematol. 2021 Apr;8(4):e242-e243. - PMID 33667421

3

ALK-positive anaplastic large-cell lymphoma in adults : an individual patient data pooled analysis of 263 patients

enthalten in: Haematologica | 2019

von Sibon, D. | Nguyen, D. | Schmitz, N. | +15

4

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial

enthalten in: British journal of haematology | 2019

von Friedrichs, B. | Nickelsen, M. | Ziepert, M. | +12

5

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Staiger, A. | Ziepert, M. | Horn, H. | +21

6

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma : an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

enthalten in: The Lancet. Oncology | 2012

von Schmitz, N. | Nickelsen, M. | Ziepert, M. | +76

CommentIn: Lancet Oncol. 2012 Dec;13(12):1180-2. - PMID 23168361

7

A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma

enthalten in: Cancer research | 2010

von Hoffmann, M. | Schirmer, M. | Tzvetkov, M. | +9

8

Equitoxicity of bolus and infusional etoposide : results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

enthalten in: Annals of hematology | 2008

von Zwick, C. | Birkmann, J. | Peter, N. | +35

1
[1]